The short version of MC1R fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-24. Anything still debated is marked as such rather than presented as settled.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
SpyTag and SpyCatcher were formed from the splitting and engineering of the CnaB2 domain of the FbaB protein from Streptococcus pyogenes, which naturally forms an intramolecular isopeptide bond to assist colonization of the host cell. With the formation of the isopeptide bond, the CnaB2 domain becomes more tolerant to conformational, thermal and pH changes. Building upon this, SpyTag was obtained from CnaB2 by extracting the C-terminal beta strand containing the reactive aspartic acid at D556 and leaving the rest of the beta strands containing the reactive lysine K470 and the catalytic glutamic acid at E516 to become SpyCatcher, after further engineering to remove some hydrophobic surface residues. The resulting SpyTag/SpyCatcher can react to form the isopeptide bond with a second-order rate constant of 1.4 ± 0.4 × 103 M−1 s−1. It is postulated that the reaction mechanism proceeds by a nucleophilic attack on D556 from K470, mediated by E516. By reconstituting SpyTag:SpyCatcher, the resulting conjugated complex acquires the stability of the parent CnaB2 domain. A second generation SpyTag/SpyCatcher called SpyTag002/SpyCatcher002 was then created through phage display that enables the peptide-protein pair to react up to 12 times faster than the original pair, at a rate constant of 2.0 ± 0.2 × 104 M−1 s−1. The second generation SpyCatcher002 also has abolished self-reactivity that is present with SpyCatcher. A third generation SpyTag/SpyCatcher called SpyTag003/SpyCatcher003 has now also been created through rational design.
=== Single-molecule explanation === The adsorption of ensemble molecules on a surface or interface can be divided into two processes: adsorption and desorption. If the adsorption rate wins the desorption rate, the molecules will accumulate over time giving the adsorption curve over time. If the desorption rate is larger, the number of molecules on the surface will decrease over time. The adsorption rate is dependent on the temperature, the diffusion rate of the solute (related to mean free path for pure gas), and the energy barrier between the molecule and the surface. The diffusion and key elements of the adsorption rate can be calculated using Fick's laws of diffusion and the Einstein relation (kinetic theory). Under ideal conditions, when there is no energy barrier and all molecules that diffuse and collide with the surface get adsorbed, the number of molecules adsorbed
, regardless of secondary structure. The modern versions of these libraries as used in most software are presented as multidimensional distributions of probability or frequency, where the peaks correspond to the dihedral-angle conformations considered as individual rotamers in the lists. Some versions are based on very carefully curated data and are used primarily for structure validation, while others emphasize relative frequencies in much larger data sets and are the form used primarily for structure prediction, such as the Dunbrack rotamer libraries. Side-chain packing methods are most useful for analyzing the protein's hydrophobic core, where side chains are more closely packed; they have more difficulty addressing the looser constraints and higher flexibility of surface residues, which often occupy multiple rotamer conformations rather than just one.
Sources: en.wikipedia.org
Electroluminescence from a solid state diode was discovered in 1906 by Henry Joseph Round of Marconi Labs, and was published in February 1907 in Electrical World. Round observed that various carborundum (silicon carbide) crystals would emit yellow, light green, orange, or blue light when a voltage was passed between the poles. A silicon carbide LED was created by Soviet inventor Oleg Losev in 1927. Commercially viable LEDs only became available after Texas Instruments engineers patented efficient near-infrared emission from a diode based on GaAs in 1962. Commercial LEDs were extremely costly and saw no practical use until Monsanto and Hewlett-Packard developed them to the point where a unit cost less than five cents in the 1970s. In the early 1990s, Shuji Nakamura, Hiroshi Amano and Isamu Akasaki developed blue light-emitting diodes, bringing white lighting and full-color LED displays into practical use. For this work, they won the 2014 Nobel Prize in Physics.
Transamination is a chemical reaction that transfers an amino group from an amino acid to an α-keto acid. This process mainly takes place in the liver. In the liver, amino groups from different amino acids are transferred to α-ketoglutarate to form glutamate. In the mitochondria, glutamate is deaminated and toxic ammonium enters the urea cycle for excretion. Another site of transamination is the skeletal muscles. In the skeletal muscles, amino groups are transferred to pyruvate, forming alanine. Alanine carries nitrogen to the liver through the glucose–alanine cycle. In biochemistry, the process occurs extensively during amino acid synthesis and is catalyzed by transaminases (aminotransferases), which requires the cofactor pyridoxal phosphate (PLP), and an α-keto acid as the acceptor of the amino group. α-ketoglutarate acts as the predominant amino-group acceptor and produces glutamate.
== Biodesulfurization implementation and pathways == It has been observed that there are sulfur-dependent bacteria that make use of the sulfur in sulfur-containing compounds in their life cycles (either in their growth or metabolic processes), producing molecules with lower/no content in sulfur. In particular, heteroaromatic compounds, namely thiophenes and their derivatives, were observed to constitute important substrates for bacteria. Biodesulfurization is an attractive alternative to sulfur removal, particularly in the crude oil fractions where there is an abundance of sulfur heterocycles. To date, pilot attempts for industrial applications have resorted to the use of whole bacterial systems, because biodesulfurization involves a sequential cascade of reactions by different enzymes and a large amount of cofactors participating in redox reactions either with the sulfur atom or molecular oxygen. However, they lacked the scalability desired for an industrial setup due to overall low enzyme efficiency, product feedback inhibition mechanisms and toxicity, or inadequate conditions for long-term bacterial growth. While cell-free recombinant enzymes would be desirable, known implementations are still well below the efficiency met for whole-cell ones. There are two main pathways through which bacteria remove sulfur from sulfur-containing compounds: ring destructive pathways and sulfur-specific pathways.
. The activation energy represents the energy difference between the initial ideally arranges state and a transition state towards the defective structure. At low defect concentrations, defect formation is entropy driven until a critical concentration of defects allows the activation energy term to compensate for entropy. There is usually an equilibrium defect density indicated at the minimum free energy. The activation energy for defect formation increases this equilibrium defect density.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.